CAS: 2364554-48-1; (R)-N-(5-(5-Ethyl-1,2,4-Oxadiazol-3-yl)-2,3-Dihydro-1H-Inden-1-yl)-1-Methyl-1H-Pyrazole-4-Carboxamide

主要参考文献

1: Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzky J, Wehri E, Robertson LA, Malik FI, Morgan BP. Discovery of Aficamten (CK-274), a Next- Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142-14152. doi: 10.1021/acs.jmedchem.1c01290. Epub 2021 Oct 4. 19(6):353-363. doi: 10.1038/s41569-022-00682-0. Epub 2022 Mar 18.
3: Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T; REDWOOD-HCM Steering Committee and Investigators. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020.
13:975076. doi: 10.3389/fphys.2022.975076. Erratum in: Front Physiol. 2022 Dec 12;13:1111059.

合成参考文献

参考文献:10.1055/s-0041-1737088
摘要:Synthesis of Aficamten. Synfacts. 2021 Nov 17;17(12):1309. doi: 10.1055/s-0041-1737088.
参考文献:10.1021/acs.jmedchem.1c01290
摘要:Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzky J, Wehri E, Robertson LA, Malik FI, Morgan BP. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142–52. doi: 10.1021/acs.jmedchem.1c01290.